Tinea Pedis also called as Athlet’s Foot is a superficial fungal infection of feet caused by group of fungi known as dermatophytes. Fungi are eukaryotic organism that live as saprophyte or parasite existing in two different forms as yeast and molds. Moist, occlusive environment is the ideal environment for the growth of such organism affecting keratin of the top layer of the epidermis. Conditions such as diabetes and HIV interfere with body’s immune system and increase the risk of getting infected with tinea pedis. The disease in more prevalent in tropic and subtropical countries of the world. FDA reports Trichophyton rubrum as the main causative agent of Tinea pedis followed by Trichophyton mentagrophytes and Epidermophyton floccosum. However in some of the cases the diseases is also caused by Microsporum canis, Trichophyton tonsurans and by other dermatophyte species.
Tinea pedis is estimated to affect 40% of the total population who visit hospital for a medical reason. The diseases is accompanied by dermatophyte infection of other parts of the body including groin, hands or nails. Clinical diagnosis of tinea pedis includes visible fissuring, maceration, and scaling in the interdigital or subdigital area of the feet. This may also involve examination of sole area of the foot characterized by diffused scaling or presence of vesicopustules on the plantar area around the instep of the foot. Tinea pedis is contagious and spreads through direct contact. Topical therapy is effective for the treatment of tinea pedis. Generally, the diseases can be treated using topical antifungals. However, patients with moccasin, vesicular tinea pedis, or persistent tinea pedis may require oral antifungal treatment.
Tinea pedis treatment market is expected to grow at a healthy pace attributed to growing number of patients with concomitant diabetes, atopy, and immunosuppression. With rapidly ageing population coupled with increasing numbers of immunocompromised patients, tinea is emerging as an important and a significantly prevalent infection over the coming years.
Skin conditions represents one of the most common health related problem affecting millions of people worldwide. The diseases is found to be more prevalent in warm and moist environments predominantly affecting the feet and toes. Shoes, showers, and pool areas are frequent culprits that foster and spread tinea pedis infections. Additionally, growing incidence of diabetes across the world is also fueling the market expected to fuel the growth of tinea pedis treatment market over the forecast period. It has been reported that 50% of the diabetic patients are at risk of developing tinea pedis at some point in their lifetime than non-diabetic patients. Tinea pedis treatment market is dominated by generics hence, big market players in the absence of any patent protection, face stiff competition from generics, leading to declining sales. Majority of products for topical treatment of tinea pedis have moderate efficacy with extended treatment time. Therefore, manufacturers of the drugs are focusing upon development of drugs that would take minimum amount of time in the treatment of tinea pedis.
Tinea pedis is a growing concern in many underdeveloped and developed countries. Lack of awareness and less patient involvement in the diseases treatment is expected to hamper the market growth over the forecast period. The condition is widespread with a high rate of recurrence leading to serious complications if not treated on time. Aging population and increasing prevalence of diabetic patients has resulted in large patient pool suffering from this diseases. However, the market for tinea pedis also represents highly commercial opportunity for novel drugs under development that could lead to greater sales thereby creating a huge opportunity for drug manufacturers. Also, presence of large number of generics in the market is expected to offer huge market growth opportunity for tinea pedis treatment market in the near future.
Region wise, the global tinea pedis treatment market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa.North America leads the global tinea pedis treatment market followed by Europe. Growing prevalence of diabetes in the region and growing number coupled with growing investment in R & D and increased FDA approvals are expected towards the revenue traction in North America. Worldwide market for tinea pedis treatment is still evolving due to dominance of generics and major drug development firms and various companies need to work in close coordination with each other in order to develop effective treatment therapies for tinea pedis diseases management.
A sample of this report is available upon request @